Compare RFL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RFL | ATNM |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 36.8M |
| IPO Year | 2017 | 2013 |
| Metric | RFL | ATNM |
|---|---|---|
| Price | $1.50 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 91.0K | ★ 109.4K |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.28 | ★ 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $917,000.00 | $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $1.02 |
| 52 Week High | $3.19 | $1.95 |
| Indicator | RFL | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 65.63 | 48.69 |
| Support Level | $1.41 | $1.02 |
| Resistance Level | $1.63 | $1.71 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 71.25 | 62.79 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.